5/31
12:08 pm
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
5/30
04:18 pm
lrmr
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia [Yahoo! Finance]
High
Report
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia [Yahoo! Finance]
5/30
04:05 pm
lrmr
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
High
Report
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
5/22
02:31 pm
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $10.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its price target raised by analysts at Citigroup Inc. from $10.00 to $14.00. They now have a "buy" rating on the stock.
5/22
12:43 pm
lrmr
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study [Yahoo! Finance]
Low
Report
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study [Yahoo! Finance]
5/21
01:24 pm
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.
5/21
05:47 am
lrmr
Biggest stock movers today: PANW, GOTU, and more [Seeking Alpha]
Medium
Report
Biggest stock movers today: PANW, GOTU, and more [Seeking Alpha]
5/20
04:18 pm
lrmr
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia [Yahoo! Finance]
High
Report
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia [Yahoo! Finance]
5/20
04:05 pm
lrmr
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Medium
Report
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
5/10
06:51 am
lrmr
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth [Yahoo! Finance]
Medium
Report
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth [Yahoo! Finance]
5/9
07:06 am
lrmr
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Low
Report
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
5/9
07:00 am
lrmr
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
Low
Report
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
4/4
08:04 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/3
08:11 am
lrmr
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.
Low
Report
Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.